Eletriptan Hydrobromide

氢溴酸依立曲坦

Report date: 2023/03/20 15:19:23
NME

Base Information

Drug NameEletriptan Hydrobromide
Drug Alias Name依来曲普坦氢溴酸盐Eletriptanum氢溴酸曲坦依来曲普坦伊立曲坦氢溴酸盐 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsMigraine without AuraMigraine with AuraMigraine Disorders
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryVenezuela
Original Approved Date2000/01/01
Country/TerritoryCzechiaBelgiumUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUpjohn IncPfizer Inc
Inactive CompaniesViatris
Active IndicationsMigraine Disorders
Inactive IndicationsMigraine without AuraMigraine with Aura

Other Information

ATC CodeN02CC06
Related LinksWikipediaDrugBankKEGG